Since intracerebral delivery of iPS-ML/NEP2 to 5XFAD mice resulted in a considerable decrease in Aβ levels in the brain interstitial fluid, these findings imply that iPS-ML/NEP2 may be a viable therapeutic agent for the treatment of AD (Takamatsu et al., 2014). This evidence concerns the gene MMEL1 and Alzheimer disease.